The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

American depositary receipts of Argenx rose after the company received approval from the Food and Drug Administration for a new delivery method of its treatment for some patients with certain ...

The FDA has approved a prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

Across the recent three months, 11 analysts have shared their insights on argenx ARGX + Free Alerts , expressing a variety of ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

for people with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and people with chronic inflammatory demyelinating polyneuropathy, argenx said.

Dianthus Therapeutics, Inc.’s DNTH share price has surged by 5.61%, which has investors questioning if this is right time to sell.

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

argenx announces FDA approval of Vyvgart Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. News release.